Wave Life Sciences Ltd’s recently made public that its insider Francis Chris unloaded Company’s shares for reported $0.15 million on Jan 02 ’26. In the deal valued at $16.03 per share,9,375 shares were sold. As a result of this transaction, Francis Chris now holds 25,000 shares worth roughly $0.35 million.
Then, GSK plc bought 1,470,000 shares, generating $27,930,000 in total proceeds. Upon buying the shares at $19.00, the 10% Owner now owns 18,245,691 shares.
Before that, Rawcliffe Adrian sold 42,000 shares. Wave Life Sciences Ltd shares valued at $630,000 were divested by the Director at a price of $15.00 per share. As a result of the transaction, Rawcliffe Adrian now holds 12,700 shares, worth roughly $0.18 million.
Wedbush reiterated its Wave Life Sciences Ltd [WVE] rating to an Outperform in a research note published on December 12, 2025; the price target was $33. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who increased its forecast for the stock in early December from “a Sector perform” to “an Outperform”. Wells Fargo began covering WVE with “an Overweight” recommendation on October 20, 2025. Canaccord Genuity started covering the stock on August 04, 2025. It rated WVE as “a Buy”.
Price Performance Review of WVE
On Monday, Wave Life Sciences Ltd [NASDAQ:WVE] saw its stock jump 0.51% to $13.91. Over the last five days, the stock has lost -7.27%. Wave Life Sciences Ltd shares have risen nearly 11.28% since the year began. Nevertheless, the stocks have fallen -18.18% over the past one year.
How much short interest is there in Wave Life Sciences Ltd?
A steep rise in short interest was recorded in Wave Life Sciences Ltd stocks on 2025-12-31, dropping by -1.33 million shares to a total of 14.69 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 16.03 million shares. There was a decline of -9.08%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on July 28, 2025 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $24 price target.
